Medicare Is Covering Weight Loss Medication for the First Time
In a historic policy shift, Medicare Part D will begin covering anti-obesity GLP-1 medications starting July 1, 2026. A temporary bridge program will cap patient copays at $50 per month through December 31, 2026.
This is unprecedented. Medicare has never covered weight loss medications before, despite covering diabetes medications (including Ozempic and Mounjaro) for years. The change affects an estimated 7+ million Medicare beneficiaries who meet BMI criteria for GLP-1 treatment.
The Medicare Price
$50/mo — maximum copay under the Medicare GLP-1 bridge program (Jul 1 – Dec 31, 2026)
How the Bridge Program Works
The Medicare GLP-1 bridge program is a temporary six-month initiative designed to provide immediate coverage while CMS develops permanent coverage rules for 2027 and beyond.
Covered medications: FDA-approved GLP-1 medications indicated for weight management, including Wegovy (semaglutide), Zepbound (tirzepatide), and potentially their injection and oral formulations.
Copay cap: $50 per month maximum out-of-pocket for the medication, regardless of the drug's list price or your Part D plan's formulary tier.
Eligibility: Medicare Part D enrollees with a BMI of 30+ (or 27+ with at least one weight-related comorbidity). A prescribing provider must document medical necessity.
Duration: July 1 through December 31, 2026. CMS will use this period to assess utilization data and develop permanent coverage policies.
What This Means for Your Costs
| Current Path (Pre-July) | Monthly Cost | After Bridge (July+) | Monthly Cost |
|---|---|---|---|
| Wegovy self-pay via NovoCare | $149–$349/mo | Wegovy via Part D | $50/mo |
| Compounded semaglutide | $146–$299/mo | Wegovy via Part D | $50/mo |
| No treatment (can't afford it) | $0 | Wegovy via Part D | $50/mo |
For Medicare beneficiaries currently paying $200+/month for compounded semaglutide, switching to Medicare-covered brand-name Wegovy at $50/month is a significant savings — and upgrades you to an FDA-approved product.
How to Prepare Now
Talk to your doctor before July. Having GLP-1 treatment documented in your medical record before the program launches will speed up the prior authorization process. Ask your provider to note your BMI, weight-related conditions, and any previous weight loss attempts in your chart.
Check your Part D plan. Contact your Part D plan administrator to ask about their timeline for implementing the bridge program. Some plans may have Wegovy or Zepbound on their formulary already for diabetes use — the bridge program extends this to weight management.
Don't wait if you need treatment now. If your health situation requires starting GLP-1 treatment before July, the manufacturer self-pay programs and compounded options described below are available today. You can transition to Medicare coverage when it kicks in.
What to Do Between Now and July
If you're on Medicare and want to start GLP-1 treatment before the bridge program begins, here are your current options:
Option 1: Brand-Name Self-Pay Programs
Novo Nordisk's NovoCare Pharmacy offers the Wegovy pill at $149/month and Wegovy injection at $199/month for new patients. These programs don't use your Medicare benefit — they're purely self-pay.
Sesame Care — FDA-Approved Medications
Real video visits with licensed providers. Access brand-name Wegovy, Ozempic, and Zepbound with manufacturer savings programs.
See Options →Sponsored
Option 2: Compounded Semaglutide
For patients eligible for compounded medications, prices start lower than the manufacturer programs and can bridge the gap until July.
MEDVi — From $179/mo
Compounded semaglutide and tirzepatide with no hidden membership fees. Injectable and oral options available. All-inclusive pricing.
Check Availability →Sponsored · Compounded medications are not FDA-approved.
Care Bare Rx — Check Current Price
Compounded GLP-1 programs with personalized support. Weight loss, wellness, and ongoing provider monitoring.
See Current Pricing →Sponsored · Compounded medications are not FDA-approved.
After December 2026: What Happens Next?
The bridge program is explicitly temporary — it expires December 31, 2026. CMS has indicated that permanent coverage rules will be developed based on utilization data from the bridge period.
Several outcomes are possible for 2027: permanent Part D coverage with standard formulary tiering, a modified bridge program extension, or new legislation mandating ongoing coverage. The political momentum behind GLP-1 coverage is strong, given that obesity affects over 40% of adults and Medicare's long-term costs for obesity-related conditions far exceed medication costs.
Regardless of what happens in 2027, the July–December 2026 bridge is confirmed. If you're on Medicare and eligible, this is the time to act.
The Bottom Line
The $50/month Medicare bridge program starting July 2026 is the most significant GLP-1 pricing development for older adults since these medications launched. For the 7+ million eligible Medicare beneficiaries, it eliminates cost as a barrier to treatment for the first time.
If you're on Medicare: talk to your doctor now, document your eligibility, and plan to enroll when the program opens July 1.
Compare all pricing options — including what's available right now — on our master pricing table.